Related Experiment Video
Updated: Jul 5, 2025
11:13
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.6K
Tibolone and Breast Cancer
Jae Kyung Lee1,2, Hyewon Yun1,2, Heeyon Kim1,2
1Departments of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Journal of Menopausal Medicine
|January 17, 2024
Summary
Tibolone, a selective estrogenic activity regulator, shows no increased breast cancer risk. This review focuses on recent studies, especially in Asian populations, regarding tibolone and breast health.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Tibolone is a synthetic steroid selective estrogenic activity regulator.
- Unlike conventional therapies, tibolone has tissue-specific effects, activating estrogenic activity in the brain, vagina, and bone.
- Tibolone is inactive in the endometrium and breast, prompting investigation into its breast cancer risk.
Purpose of the Study:
- To determine the effects of tibolone on breast tissue.
- To investigate the relationship between tibolone use and breast cancer risk.
- To focus on recent studies, particularly those involving Asian populations.
Main Methods:
- Review of recent scientific literature.
- Analysis of studies investigating tibolone's impact on breast health.
- Emphasis on epidemiological data from Asian populations.
Main Results:
- Tibolone does not appear to increase the risk of breast cancer.
- Estrogenic activity is localized, sparing breast tissue.
- Recent research, including Asian studies, supports a neutral or potentially protective effect.
Conclusions:
- Tibolone is a safe menopausal hormone therapy option regarding breast cancer risk.
- Selective tissue estrogenic activity regulation offers benefits without typical risks.
- Further research in diverse populations is warranted but current evidence is reassuring.
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:27Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
01:16TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K